United States : Corporate Booth to Include Virtual Tour of Myford Late-Stage Clinical and Commercial Biomanufacturing Facility Highlighting Immedia... - EUCLID Procurement
10-Aug-2018 00:37
United States : Corporate Booth to Include Virtual Tour of Myford Late-Stage
Clinical and Commercial Biomanufacturing Facility Highlighting Immediately
Available 2,000-Liter Scale Bioreactor Capacity
Avid Bioservices, Inc. a dedicated biologics contract development and
manufacturing organization (CDMO) working to improve patient lives by
providing high quality development and manufacturing services to biotechnology
and pharmaceutical companies, today announced that the company will exhibit at
the upcoming Bioprocessing Summit 2018. Avid will host a corporate booth
(#310) in the conference?s exhibit hall, where it will showcase the company?s
comprehensive range of process development, high quality cGMP clinical and
commercial manufacturing services. The Bioprocessing Summit 2018 is being held
August 13-17, 2018 in Boston, MA.
As part of its exhibit at the Bioprocessing Summit 2018, Avid will provide a
virtual tour of the company?s 42,000 square foot state-of-the-art commercial
biomanufacturing suite (Myford facility), which is in the unique position of
being a validated facility with immediately available 2,000-liter scale
bioreactor capacity. The company will also discuss the ongoing expansion of
its process development capabilities and laboratories.
The Myford facility, located in Tustin, California, incorporates a variety of
cutting-edge, single-use equipment with the goal of ultimately accommodating a
fully disposable biomanufacturing process. A wide range of innovative features
are incorporated into the facility including monolithic modular clean rooms,
dedicated support utilities for each key processing area, and the industry?s
most advanced single-use production systems and flexible solutions.
Uni-directional process flows separate personnel and materials and provide
assurance that the design meets the most stringent regulatory requirements for
commercial biologics drug substance manufacturing. This facility complements
Avid?s legacy commercial facility, located on the same campus, which continues
to be responsible for the manufacture of multiple globally marketed commercial
products.
Copyright (c) 2018 Euclid Infotech Pvt Ltd.Copyright (c) 2018 Euclid Infotech Pvt Ltd.
nNRA6nnjgk
----------
(C) Thomson Reuters 2018. All rights reserved. The Thomson Reuters content received through this service is the intellectual property of Thomson Reuters or its third party suppliers. Republication or redistribution of content provided by Thomson Reuters is expressly prohibited without the prior written consent of Thomson Reuters, except where permitted by the terms of the relevant Thomson Reuters service agreement. Neither Thomson Reuters nor its third party suppliers shall be liable for any errors, omissions or delays in content, or for any actions taken in reliance thereon. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.
